Mesenchymal stem cells
a new perspective in the treatment of coronavirus-induced pneumonia (COVID-19)
DOI:
https://doi.org/10.11606/issn.1679-9836.v99i3p272-277Keywords:
Coronavirus infections, Coronavirus, Mesenchymal stem cells, Pneumonia, Respiratory diseasesAbstract
The biology of stem cells is one of the most dynamic and promising fields in the biological sciences, as it is the basis for the development of organisms. Its biological complexity has demanded efforts from several lines of research aiming mainly at its therapeutic use. Mesenchymal stem cells (MSCs), after their infusion into the recipient organism, tend to accumulate in the lung, improving the microenvironment, protecting the epithelial cells of the alveoli and preventing the formation of fibrosis in order to restore the function of the lungs. Through safe and effective processes to suppress inflammatory processes and repair lung tissue, MSCs appear as a promising therapeutic approach for the treatment of respiratory diseases. In this work, we address the state of the art and the therapeutic potential of MSCs in the treatment of patients affected by pneumonia in COVID-19.
Downloads
References
Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1:76-7. doi: 10.1016/s0140-6736(66)92364-6.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23. doi: 10.1007/978-1-4939-2438-7_1.
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and Pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502. doi: 10.1016/j.tim.2016.03.003. Epub 2016 Mar 21.
Jeffrey SK, Kenneth M. History and Recent Advances in Coronavirus Discovery. Pediatr Infect Dis J. 2005;24(11 Suppl):S223-7, discussion S226. doi: 10.1097/01.inf.0000188166.17324.60.
Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310(5748):676-9. doi: 10.1126/science.1118391.
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92. doi: 10.1038/s41579-018-0118-9.
Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-20. doi: 10.1056/NEJMoa1211721.
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-61. doi: 10.1016/S1473-3099(13)70204-4.
World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2019 Nov 1]. Available from: http://www.who.int/emergencies/mers-cov.
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. doi: 10.1016/S0140-6736(20)30251-8.
Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25:35-48. doi: 10.1016/j.tim.2016.09.001.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. doi: 10.1038/s41586-020-2008-3
Chen S. Coronavirus: critically ill Chinese patient saved by stem cell therapy, study says. South China Morning Post, March 2, 2020 [cited March 18, 2020]. Available from: www.scmp.com/news/china/society/ article/3053080/coronavirus-criticallyill-chinese-patient-saved-stem-cell.
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7. doi: 10.1002/jmv.25689.
Guo YR, Cao Q, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0.
Barbas CSV, Matos GFJ. Síndrome do desconforto respiratório agudo: definição. Pulmão (Rio de Janeiro). 2011;20(1):1-6. Disponível em: http://www.sopterj.com.br/wp-content/themes/_sopterj_redesign_2017/_revista/2011/n_01/01.pdf.
Ricardo JJ, Ari M. COVID-19 Cytocine storm the interplay between inflammation and coagulation. Lancet Respir Med.. 2020 Apr 27;S2213-2600(20)30216-2. doi: 10.1016/S2213-2600(20)30216-2.
Mehta P, McAuley P, Brown M, Sanchez E, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0.
O’Dwyer DN, Gurczynski SJ, Moore BB. Pulmonary immunity and extracellular matrix interactions. Matrix Biol. 2018;73:122-34. doi: 10.1016/j.matbio.2018.04.003.
Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper MS. Stem cell therapy for neurological disorders. S Afr Med J. 2019;109(8b):70-7. doi: 10.7196/SAMJ.2019.v109i8b.14009.
Doyle EC, Wragg NM, Wilson SL. Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020 Jan 31. doi: 10.1007/s00167-020-05859-z.
Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immunemediated diseases. Stem Cell Rev. 2015;11(2):280-7. doi: 10.1007/s12015-014-9583-3.
Xu T, Zhang Y, Chang P, Gong S, Shao L, Dong L. Mesenchymal stem cell-based therapy for radiation-induced lung injury. Stem Cell Res Ther. 2018;9(1):18. doi: 10.1186/s13287-018-0776-6.
Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106(38):16357-62. doi: 10.1073/pnas.0907996106.
Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production [published correction appears in Nat Med. 2009 Apr;15(4):462]. Nat Med. 2009;15(1):42-9. doi: 10.1038/nm.1905.
Hu S, Li J, Xu X, Liu A, He H, Xu J, Chen Q, Liu S, Liu L, Qiu H, Yang Y. The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo. Stem Cell Res Ther. 2016;7(1):66. doi: 10.1186/s13287-016-0320-5.
Yang Y, Hu S, Xu X, Li J, Liu A, Han J, Liu S, Liu L, Qiu H. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Mediators Inflamm. 2016;2016:2347938. doi: 10.1155/2016/2347938.
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216-28. doi: 10.14336/AD.2020.0228.
Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Nie P, Qian C. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. ChinaXiv 2020. Available frm: http://chinaxiv.org/user/download.htm?id=30285.
